Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 1998;31:925-928

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zee, R. Y. L.
Right arrow Articles by Lindpaintner, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zee, R. Y. L.
Right arrow Articles by Lindpaintner, K.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Cough

(Hypertension. 1998;31:925-928.)
© 1998 American Heart Association, Inc.


Scientific Contributions

Three Candidate Genes and Angiotensin-Converting Enzyme Inhibitor–Related Cough

A Pharmacogenetic Analysis

Robert Y. L. Zee; Valluri S. Rao; Robert Z. Paster; Charles S. Sweet; ; Klaus Lindpaintner

From the Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital (R.Y.L.Z., V.S.R., K.L.), and the Department of Cardiology, Children's Hospital, Harvard Medical School (K.L.), Boston, Mass; the Dean Medical Center, Oregon, Wisc (R.Z.P.); the Merck Research Laboratories, West Point, Pa (C.S.S.); the Max Delbruck Centre for Molecular Medicine, Berlin, Germany (K.L.); and the Cardiovascular Discovery Unit, F. Hoffmann-La Roche Ltd, Basel, Switzerland (K.L.).

Correspondence to Klaus Lindpaintner, MD, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115. E-mail kl{at}calvin.bwh.harvard.edu

Abstract—Unexplained, persistent cough limits the use of angiotensin-converting enzyme (ACE) inhibitors in a significant number of patients. It has been speculated that occurrence of this adverse effect is genetically predetermined; in particular, variants of the genes encoding ACE, chymase, and B2-bradykinin receptor have been implicated. To investigate this question, we determined genotypes for common polymorphisms for these three genes in subjects with a history of ACE inhibitor–related cough. Specificity of the adverse effect was confirmed by a blinded, double-crossover design protocol in which subjects were rechallenged with either lisinopril or placebo. In 99 case subjects and 70 control subjects (who failed to develop cough on rechallenge with ACE inhibitor) thus selected, frequencies for the ACE D and I alleles were 0.56 and 0.44 (cases) and 0.56 and 0.44 (controls), respectively; frequencies for chymase A and B alleles (absence/presence of BstXI site) were 0.56 and 0.44 (cases) and 0.46 and 0.54 (controls), respectively; frequencies for B2-bradykinin receptor + and - alleles (presence/absence of a 21 to 29 nonanucleotide sequence) were 0.52 and 0.48 (cases) and 0.53 and 0.47 (controls), respectively. All observed genotype frequencies were in Hardy-Weinberg equilibrium. There was no evidence for association between genotype at either gene examined and cough (adjusted for gender and age). Our data indicate that common genetic variants of ACE, chymase, and B2-bradykinin receptor do not explain the occurrence of ACE inhibitor–related cough.


Key Words: angiotensin-converting enzyme inhibitors • cough • angiotensin-converting enzyme • chymase • receptors, bradykinin • polymorphism • genetics




This article has been cited by other articles:


Home page
Journal of Pharmacy PracticeHome page
S. J. Herner, S. A. Kinikar, L. A. Miyashiro, and S. J. Billups
Interventional Case Series: Angiotensin-Converting Enzyme Inhibitor (ACE-I)-Induced Cough: Is Rechallenge With a Second ACE-I Worthwhile?
Journal of Pharmacy Practice, October 1, 2009; 22(5): 508 - 512.
[Abstract] [PDF]


Home page
Pharmacol. Rev.Home page
L. M. F. Leeb-Lundberg, F. Marceau, W. Muller-Esterl, D. J. Pettibone, and B. L. Zuraw
International Union of Pharmacology. XLV. Classification of the Kinin Receptor Family: from Molecular Mechanisms to Pathophysiological Consequences
Pharmacol. Rev., March 1, 2005; 57(1): 27 - 77.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
L. P. A. McGarvey, D. A. Savage, S. A. Feeney, L. G. Heaney, M. Ennis, J. MacMahon, and A. P. Maxwell
Is There an Association Between Angiotensin-Converting Enzyme Gene Variants and Chronic Nonproductive Cough?
Chest, October 1, 2000; 118(4): 1091 - 1094.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Houle, M. Landry, R. Audet, J. Bouthillier, D. R. Bachvarov, and F. Marceau
Effect of Allelic Polymorphism of the B1 and B2 Receptor Genes on the Contractile Responses of the Human Umbilical Vein to Kinins
J. Pharmacol. Exp. Ther., July 1, 2000; 294(1): 45 - 51.
[Abstract] [Full Text]


Home page
HypertensionHome page
S. Mukae, S. Aoki, S. Itoh, T. Iwata, H. Ueda, and T. Katagiri
Bradykinin B2 Receptor Gene Polymorphism Is Associated With Angiotensin-Converting Enzyme Inhibitor-Related Cough
Hypertension, July 1, 2000; 36(1): 127 - 131.
[Abstract] [Full Text] [PDF]